Wet Age-Related Macular Degeneration Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 - DelveInsight

DelveInsight's "Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Wet Age-Related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Wet Age-Related Macular Degeneration Market Forecast
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Wet Age-Related Macular Degeneration Market Report:
• In 2023, the United States held the largest market share for Wet Age-Related Macular Degeneration (Wet AMD) among the 7MM, with a value of around USD 2,599 million. This market is projected to grow at a CAGR of 6.6% through 2036.
• In July 2026, The U.S. Food and Drug Administration (FDA) has approved bevacizumab-vikg (ONS-5010/LYTENAVA), developed by Outlook Therapeutics, for the treatment of wet age-related macular degeneration (wet AMD). According to the company, the approval makes LYTENAVA the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States.
• In June 2026, Clinical development in the Wet Age-Related Macular Degeneration (Wet AMD) landscape continued to progress, with ongoing research into gene therapies, sustained-release drug delivery systems, biosimilars, and next-generation anti-VEGF treatments. These investigational approaches are focused on delivering longer-lasting therapeutic benefits, minimizing the need for frequent intravitreal injections, and maintaining or improving patients' visual outcomes.
• In April 2026, Regeneron Pharmaceuticals, Inc. announced that the US FDA approved extending dosing intervals for EYLEA HD (aflibercept) up to every 20 weeks in wet AMD and Diabetic Macular Edema (DME) patients after one year of response, supported by 2-year data from the PULSAR and PHOTON trials showing sustained efficacy and safety.
• In February 2026, Several biopharmaceutical companies continued to advance Phase II and Phase III clinical trials for next-generation Wet Age-Related Macular Degeneration (Wet AMD) treatments. These investigational therapies include long-acting anti-VEGF agents and gene therapies aimed at reducing the need for frequent intravitreal injections while preserving or improving visual outcomes.
• In January 2026, The FDA issued a third complete response letter (CRL) for Outlook Therapeutics' ONS-5010/Lytenava, intended for the treatment of wet age-related macular degeneration (wet AMD). The agency advised the company to submit confirmatory evidence demonstrating efficacy, noting that the additional mechanistic and natural-history data included in the resubmitted biologics license application (BLA) did not alter its earlier review conclusions. Age-related macular degeneration develops when the macula-a central part of the retina responsible for sharp vision-sustains damage. Approximately 10% of AMD cases progress to the wet form, also known as neovascular AMD, which causes vision loss due to abnormal blood vessel growth between retinal cell layers.
• In September 2025, Findings from the AVONELLE-X extension study (NCT04777201) and the Phase IIIb/IV SALWEEN trial revealed that Roche's Vabysmo (faricimab) delivered significant clinical benefits for patients with wet age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). The company stated that Vabysmo marks an important step forward in treating these conditions, addressing unmet needs in vision care and supporting sustained disease management.
• In July 2025, EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), focused on developing and commercializing innovative therapies for serious retinal diseases, announced the completion of patient enrollment in its Phase 3 pivotal program with the full enrollment of the LUCIA trial. LUCIA is the second of two identical ongoing pivotal non-inferiority studies assessing DURAVYUTM for treating wet age-related macular degeneration (wet AMD). The first pivotal study, LUGANO, finished enrollment in May 2025. More than 400 patients were enrolled and randomized in LUCIA within seven months, making DURAVYU one of the fastest-enrolling Phase 3 pivotal programs in wet AMD.
• In April 2025, Outlook Therapeutics announced that the U.S. FDA has accepted the resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab intended for the treatment of wet age-related macular degeneration (wet AMD).
• In March 2025, Opthea decided to halt its COAST and ShORe clinical trials for wet age-related macular degeneration (AMD) after the COAST study failed to achieve its primary endpoint. The company also expedited the release of topline data from the ShORe trial, which similarly did not meet its primary goal of improving best corrected visual acuity (BCVA) from baseline to week 52. The global Phase 3 ShORe study assessed the efficacy and safety of intravitreal 2 mg sozinibercept administered every 4 or 8 weeks alongside 0.5 mg ranibizumab every 4 weeks, compared to ranibizumab monotherapy.
• The Wet AMD market is evolving as treatment focus shifts from conventional anti-VEGF therapies (e.g., ranibizumab, aflibercept, and bevacizumab) toward longer-acting and innovative approaches, with high-dose formulations such as EYLEA HD (aflibercept), sustained delivery systems like ranibizumab (LUCENTIS) , and emerging gene therapies driving adoption due to improved durability, reduced treatment burden, and better patient compliance.
• Regional market dynamics show the United States leading in revenue, while Japan and European Union markets demonstrate steady growth, supported by increasing disease awareness, aging populations, and rising uptake of advanced and long-acting treatment options.
• According to DelveInsight's estimates, the total prevalent cases of Wet AMD in the 7MM were approximately 3 million in 2025.
• The age-specific distribution of Wet AMD in the US demonstrates a substantial increase with advancing age, with the highest prevalence observed among individuals aged ≥85 years, highlighting the growing epidemiological burden in the elderly population and the need for timely diagnosis and management to reduce vision-related complication.
• In 2025, early and intermediate AMD accounted for the majority of stage-specific AMD cases, whereas late-stage AMD (nAMD and geographic atrophy) represented a significantly smaller proportion, highlighting that most patients are diagnosed before progression to advanced disease stages, in Japan.
• Key Wet Age-Related Macular Degeneration Companies: Neuracle Genetics, Inc, EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Outlook Therapeutics, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience, 4D Molecular Therapeutics, Michel Giunta, Bio-Thera Solutions, Sylentis, S.A., Shanghai Henlius Biotech, Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Skyline Therapeutics, AsclepiX Therapeutics, Novartis, Shanghai Refreshgene Tech, Hangzhou Jiayin Biotech Ltd, TOT Biopharm Co., Ltd., Hoffmann-La Roche, Genentech, Inc., Innovent Biologics (Suzhou) Co. Ltd., AO GENERIUM, Bayer, and others
• Key Wet Age-Related Macular Degeneration Therapies: ONS-5010, OPT-302, SYL1801, BI 836880, NG101 AAV gene therapy, Eyp-1901, RC28-E, bevacizumab, Ranibizumab, MW02, 4D-150 IVT, Aflibercept, BAT5906 injection, SYL1801, HLX04-O, ADVM-022, OTX-TKI (axitinib implant), CLS-AX, SKG0106, AXT107, Iptacopan (LNP023), RRG001, EXG102-031, TAB014, Faricimab, LUCENTIS (ranibizumab injection), Aflibercept Ophthalmic, GNR-067, BAY86-5321, and others
• The Wet Age-Related Macular Degeneration epidemiology based on gender analyzed that prevalence of Dry Age-Related Macular Degeneration is higher than Wet Age-Related Macular Degeneration
• The Wet Age-Related Macular Degeneration market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Wet Age-Related Macular Degeneration pipeline products will significantly revolutionize the Wet Age-Related Macular Degeneration market dynamics.

Wet Age-Related Macular Degeneration Overview
Wet Age-Related Macular Degeneration (Wet AMD) is a chronic eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. It is a progressive disease that can lead to significant vision loss if left untreated.

Get a Free sample for the Wet Age-Related Macular Degeneration Market Report:
https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Wet Age-Related Macular Degeneration Epidemiology
The Wet Age-Related Macular Degeneration epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Wet Age-Related Macular Degeneration Epidemiology Segmentation:
The Wet Age-Related Macular Degeneration market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalent Cases of AMD
• Stage-specific Cases of AMD
• Total Prevalent Cases of Wet AMD
• Total Diagnosed Prevalent Cases of Wet AMD
• Age-specific Cases of Wet AMD
• Total Treated Cases of Wet-AMD

Download the report to understand which factors are driving Wet Age-Related Macular Degeneration epidemiology trends @ Wet Age-Related Macular Degeneration Epidemiology Forecast
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Wet Age-Related Macular Degeneration Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Wet Age-Related Macular Degeneration market or expected to get launched during the study period. The analysis covers Wet Age-Related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Wet Age-Related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Wet Age-Related Macular Degeneration Therapies and Key Companies
• ONS-5010: Outlook Therapeutics
• OPT-302: Opthea
• SYL1801: Sylentis
• BI 836880: Boehringer Ingelheim
• NNG101 AAV gene therapy: Neuracle Genetics, Inc
• Eyp-1901: EyePoint Pharmaceuticals, Inc.
• RC28-E: RemeGen Co., Ltd.
• bevacizumab: Outlook Therapeutics
• Ranibizumab: Sinocelltech Ltd.
• MW02: Mabwell (Shanghai) Bioscience
• 4D-150 IVT: 4D Molecular Therapeutics
• Aflibercept: Michel Giunta
• BAT5906 injection: Bio-Thera Solutions
• SYL1801: Sylentis, S.A.
• HLX04-O: Shanghai Henlius Biotech
• ADVM-022: Adverum Biotechnologies, Inc.
• OTX-TKI (axitinib implant): Ocular Therapeutix, Inc.
• CLS-AX: Clearside Biomedical, Inc.
• SKG0106: Skyline Therapeutics
• AXT107: AsclepiX Therapeutics
• Iptacopan (LNP023): Novartis
• RRG001: Shanghai Refreshgene Tech
• EXG102-031: Hangzhou Jiayin Biotech Ltd
• TAB014: TOT Biopharm Co., Ltd.
• Faricimab: Hoffmann-La RocheLUCENTIS (ranibizumab injection): Genentech, Inc.
• Aflibercept Ophthalmic: Innovent Biologics (Suzhou) Co. Ltd.
• GNR-067: AO GENERIUM
• BAY86-5321: Bayer

Discover more about therapies set to grab major Wet Age-Related Macular Degeneration market share @ Wet Age-Related Macular Degeneration Treatment Market
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Wet Age-Related Macular Degeneration Market Drivers
• Rising Aging Population: The growing global elderly population is increasing the prevalence of Wet AMD, driving demand for effective treatment options.
• Advancements in Anti-VEGF Therapies: The introduction of long-acting anti-VEGF agents and sustained-release formulations is improving patient outcomes and reducing treatment burden.
• Robust Pipeline of Innovative Therapies: Strong clinical development of gene therapies, bispecific antibodies, complement inhibitors, and novel drug delivery platforms is expanding the treatment landscape.
• Increasing Awareness and Early Diagnosis: Improved screening programs, advanced retinal imaging technologies (OCT and OCT-A), and greater disease awareness are facilitating earlier diagnosis and intervention.
• Growing Healthcare Expenditure: Rising investments in ophthalmic care, favorable reimbursement policies in developed markets, and improved access to specialty eye care support market growth.

Wet Age-Related Macular Degeneration Market Barriers
• High Treatment Costs: Anti-VEGF therapies and emerging biologics are expensive, limiting affordability and access in many healthcare systems.
• Frequent Intravitreal Injections: Current standard therapies often require repeated injections, resulting in poor patient compliance and increased treatment burden.
• Limited Long-Term Durability: Many approved therapies have limited duration of action, necessitating ongoing treatment and regular monitoring.
• Risk of Disease Recurrence: Despite treatment advances, recurrence of neovascular activity remains a significant clinical challenge.
• Stringent Regulatory Requirements: Lengthy clinical development timelines and rigorous regulatory approval processes can delay market entry for novel therapies.

Scope of the Wet Age-Related Macular Degeneration Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Wet Age-Related Macular Degeneration Companies: Neuracle Genetics, Inc, EyePoint Pharmaceuticals, Inc., RemeGen Co., Ltd., Outlook Therapeutics, Sinocelltech Ltd., Mabwell (Shanghai) Bioscience, 4D Molecular Therapeutics, Michel Giunta, Bio-Thera Solutions, Sylentis, S.A., Shanghai Henlius Biotech, Adverum Biotechnologies, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Skyline Therapeutics, AsclepiX Therapeutics, Novartis, Shanghai Refreshgene Tech, Hangzhou Jiayin Biotech Ltd, TOT Biopharm Co., Ltd., Hoffmann-La Roche, Genentech, Inc., Innovent Biologics (Suzhou) Co. Ltd., AO GENERIUM, Bayer, and others
• Key Wet Age-Related Macular Degeneration Therapies: ONS-5010, OPT-302, SYL1801, BI 836880, NG101 AAV gene therapy, Eyp-1901, RC28-E, bevacizumab, Ranibizumab, MW02, 4D-150 IVT, Aflibercept, BAT5906 injection, SYL1801, HLX04-O, ADVM-022, OTX-TKI (axitinib implant), CLS-AX, SKG0106, AXT107, Iptacopan (LNP023), RRG001, EXG102-031, TAB014, Faricimab, LUCENTIS (ranibizumab injection), Aflibercept Ophthalmic, GNR-067, BAY86-5321, and others
• Wet Age-Related Macular Degeneration Therapeutic Assessment: Wet Age-Related Macular Degeneration current marketed and Wet Age-Related Macular Degeneration emerging therapies
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration market drivers and Wet Age-Related Macular Degeneration market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Wet Age-Related Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Wet Age-Related Macular Degeneration Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.